# Varonis Systems Inc: financial statements, quarterly

VRNS · Nasdaq · CIK 1361113 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vrns.md) · [Financials](/companies/vrns/financials.md) · [Filings](/companies/vrns/filings.md) · [Insiders](/companies/vrns/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vrns/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [122](/filings/0001628280-24-044561.md) | [154 d](/filings/0001628280-26-005450.md) | [114](/filings/0001628280-25-023196.md) | [130](/filings/0001628280-25-036728.md) | [148](/filings/0001628280-25-047145.md) | [159 d](/filings/0001628280-26-005450.md) | [136](/filings/0001628280-26-028411.md) | [152](/filings/0001628280-26-050630.md) | [162](/filings/0001628280-25-047145.md) | [173 d](/filings/0001628280-26-005450.md) | [173](/filings/0001628280-26-028411.md) | [180](/filings/0001628280-26-050630.md) |
| Cost of revenue | $m | [17.4](/filings/0001628280-24-044561.md) | [19.3 d](/filings/0001628280-26-005450.md) | [21.3](/filings/0001628280-25-023196.md) | [22.4](/filings/0001628280-25-036728.md) | [24.0](/filings/0001628280-25-047145.md) | [26.1 d](/filings/0001628280-26-005450.md) | [29.0](/filings/0001628280-26-028411.md) | [31.2](/filings/0001628280-26-050630.md) | [35.1](/filings/0001628280-25-047145.md) | [36.6 d](/filings/0001628280-26-005450.md) | [41.6](/filings/0001628280-26-028411.md) | [44.5](/filings/0001628280-26-050630.md) |
| Gross profit | $m | [105](/filings/0001628280-24-044561.md) | [135 d](/filings/0001628280-26-005450.md) | [92.7](/filings/0001628280-25-023196.md) | [108](/filings/0001628280-25-036728.md) | [124](/filings/0001628280-25-047145.md) | [132 d](/filings/0001628280-26-005450.md) | [107](/filings/0001628280-26-028411.md) | [121](/filings/0001628280-26-050630.md) | [126](/filings/0001628280-25-047145.md) | [137 d](/filings/0001628280-26-005450.md) | [132](/filings/0001628280-26-028411.md) | [136](/filings/0001628280-26-050630.md) |
| Research and development | $m | [44.8](/filings/0001628280-24-044561.md) | [48.1 d](/filings/0001628280-26-005450.md) | [47.8](/filings/0001628280-25-023196.md) | [44.9](/filings/0001628280-25-036728.md) | [53.5](/filings/0001628280-25-047145.md) | [50.5 d](/filings/0001628280-26-005450.md) | [54.2](/filings/0001628280-26-028411.md) | [56.2](/filings/0001628280-26-050630.md) | [62.7](/filings/0001628280-25-047145.md) | [64.6 d](/filings/0001628280-26-005450.md) | [69.8](/filings/0001628280-26-028411.md) | [73.3](/filings/0001628280-26-050630.md) |
| Operating income | $m | [(29.1)](/filings/0001628280-24-044561.md) | [(5.2) d](/filings/0001628280-26-005450.md) | [(47.6)](/filings/0001628280-25-023196.md) | [(28.8)](/filings/0001628280-25-036728.md) | [(23.6)](/filings/0001628280-25-047145.md) | [(17.6) d](/filings/0001628280-26-005450.md) | [(43.8)](/filings/0001628280-26-028411.md) | [(36.6)](/filings/0001628280-26-050630.md) | [(35.9)](/filings/0001628280-25-047145.md) | [(30.3) d](/filings/0001628280-26-005450.md) | [(44.5)](/filings/0001628280-26-028411.md) | [(40.6)](/filings/0001628280-26-050630.md) |
| Income tax | $m | [2.5](/filings/0001628280-24-044561.md) | [1.1 d](/filings/0001628280-26-005450.md) | [1.4](/filings/0001628280-25-023196.md) | [3.4](/filings/0001628280-25-036728.md) | [4.9](/filings/0001628280-25-047145.md) | [3.0 d](/filings/0001628280-26-005450.md) | [4.0](/filings/0001628280-26-028411.md) | [4.2](/filings/0001628280-26-050630.md) | [1.8](/filings/0001628280-25-047145.md) | [3.0 d](/filings/0001628280-26-005450.md) | [(3.2)](/filings/0001628280-26-028411.md) | [5.4](/filings/0001628280-26-050630.md) |
| Net income | $m | [(23.0)](/filings/0001628280-24-044561.md) | [(0.9) d](/filings/0001628280-26-005450.md) | [(40.5)](/filings/0001628280-25-047145.md) | [(23.9)](/filings/0001628280-25-047145.md) | [(18.3)](/filings/0001628280-25-047145.md) | [(13.0) d](/filings/0001628280-26-005450.md) | [(35.8)](/filings/0001628280-26-050630.md) | [(35.8)](/filings/0001628280-26-050630.md) | [(29.9)](/filings/0001628280-25-047145.md) | [(27.8) d](/filings/0001628280-26-005450.md) | [(36.9)](/filings/0001628280-26-050630.md) | [(46.8)](/filings/0001628280-26-050630.md) |
| Diluted EPS | $ per share | [(0.21)](/filings/0001628280-24-044561.md) | not reported | [(0.37)](/filings/0001628280-25-023196.md) | [(0.21)](/filings/0001628280-25-036728.md) | [(0.16)](/filings/0001628280-25-047145.md) | not reported | [(0.32)](/filings/0001628280-26-028411.md) | [(0.32)](/filings/0001628280-26-050630.md) | [(0.26)](/filings/0001628280-25-047145.md) | not reported | [(0.32)](/filings/0001628280-26-028411.md) | [(0.41)](/filings/0001628280-26-050630.md) |
| Basic EPS | $ per share | [(0.21)](/filings/0001628280-24-044561.md) | not reported | [(0.37)](/filings/0001628280-25-023196.md) | [(0.21)](/filings/0001628280-25-036728.md) | [(0.16)](/filings/0001628280-25-047145.md) | not reported | [(0.32)](/filings/0001628280-26-028411.md) | [(0.32)](/filings/0001628280-26-050630.md) | [(0.26)](/filings/0001628280-25-047145.md) | not reported | [(0.32)](/filings/0001628280-26-028411.md) | [(0.41)](/filings/0001628280-26-050630.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [111](/filings/0001628280-23-035726.md) | [231](/filings/0001628280-25-004187.md) | [147](/filings/0001628280-24-021113.md) | [155](/filings/0001628280-24-033477.md) | [282](/filings/0001628280-24-044561.md) | [186](/filings/0001628280-26-005450.md) | [153](/filings/0001628280-25-023196.md) | [199](/filings/0001628280-25-036728.md) | [157](/filings/0001628280-25-047145.md) | [202](/filings/0001628280-26-050630.md) | [179](/filings/0001628280-26-028411.md) | [234](/filings/0001628280-26-050630.md) |
| Current assets | $m | [686](/filings/0001628280-23-035726.md) | [767](/filings/0001628280-25-004187.md) | [708](/filings/0001628280-24-021113.md) | [816](/filings/0001628280-24-033477.md) | [1,074](/filings/0001628280-24-044561.md) | [878](/filings/0001628280-26-005450.md) | [818](/filings/0001628280-25-023196.md) | [1,068](/filings/0001628280-25-036728.md) | [961](/filings/0001628280-25-047145.md) | [1,299](/filings/0001628280-26-050630.md) | [1,081](/filings/0001628280-26-028411.md) | [997](/filings/0001628280-26-050630.md) |
| Total assets | $m | [1,021](/filings/0001628280-23-035726.md) | [1,104](/filings/0001628280-25-004187.md) | [1,054](/filings/0001628280-24-021113.md) | [1,095](/filings/0001628280-24-033477.md) | [1,521](/filings/0001628280-24-044561.md) | [1,664](/filings/0001628280-26-005450.md) | [1,577](/filings/0001628280-25-023196.md) | [1,615](/filings/0001628280-25-036728.md) | [1,665](/filings/0001628280-25-047145.md) | [1,792](/filings/0001628280-26-050630.md) | [1,635](/filings/0001628280-26-028411.md) | [1,654](/filings/0001628280-26-050630.md) |
| Current liabilities | $m | [267](/filings/0001628280-23-035726.md) | [307](/filings/0001628280-25-004187.md) | [297](/filings/0001628280-24-021113.md) | [334](/filings/0001628280-24-033477.md) | [594](/filings/0001628280-24-044561.md) | [710](/filings/0001628280-26-005450.md) | [710](/filings/0001628280-25-023196.md) | [771](/filings/0001628280-25-036728.md) | [532](/filings/0001628280-25-047145.md) | [659](/filings/0001628280-26-050630.md) | [639](/filings/0001628280-26-028411.md) | [606](/filings/0001628280-26-050630.md) |
| Shareholders' equity | $m | [445](/filings/0001628280-24-044561.md) | [490](/filings/0001628280-26-005450.md) | [452](/filings/0001628280-25-047145.md) | [459](/filings/0001628280-25-047145.md) | [429](/filings/0001628280-25-047145.md) | [456](/filings/0001628280-26-050630.md) | [368](/filings/0001628280-26-050630.md) | [341](/filings/0001628280-26-050630.md) | [605](/filings/0001628280-25-047145.md) | [599](/filings/0001628280-26-050630.md) | [454](/filings/0001628280-26-050630.md) | [444](/filings/0001628280-26-050630.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [6.3 d](/filings/0001628280-24-044561.md) | [10.4 d](/filings/0001628280-26-005450.md) | [56.7](/filings/0001628280-25-023196.md) | [11.7 d](/filings/0001628280-25-036728.md) | [22.5 d](/filings/0001628280-25-047145.md) | [24.3 d](/filings/0001628280-26-005450.md) | [68.0](/filings/0001628280-26-028411.md) | [21.3 d](/filings/0001628280-26-050630.md) | [33.4 d](/filings/0001628280-25-047145.md) | [24.7 d](/filings/0001628280-26-005450.md) | [55.0](/filings/0001628280-26-028411.md) | [25.1 d](/filings/0001628280-26-050630.md) |
| Capital expenditure | $m | [0.3 d](/filings/0001628280-24-044561.md) | [2.2 d](/filings/0001628280-26-005450.md) | [0.3](/filings/0001628280-25-023196.md) | [0.8 d](/filings/0001628280-25-036728.md) | [1.2 d](/filings/0001628280-25-047145.md) | [4.4 d](/filings/0001628280-26-005450.md) | [2.3](/filings/0001628280-26-028411.md) | [3.4 d](/filings/0001628280-26-050630.md) | [3.0 d](/filings/0001628280-25-047145.md) | [3.9 d](/filings/0001628280-26-005450.md) | [5.0](/filings/0001628280-26-028411.md) | [4.4 d](/filings/0001628280-26-050630.md) |
| Share repurchases | $m | [35.9 d](/filings/0001628280-24-044561.md) | [0.0 d](/filings/0001628280-26-005450.md) | [0.0](/filings/0001628280-25-023196.md) | [0.0 d](/filings/0001628280-25-036728.md) | [0.0 d](/filings/0001628280-25-047145.md) | [0.0 d](/filings/0001628280-26-005450.md) | [61.3](/filings/0001628280-26-028411.md) | [38.7 d](/filings/0001628280-26-050630.md) | [0.0 d](/filings/0001628280-25-047145.md) | [15.0 d](/filings/0001628280-26-005450.md) | [135](/filings/0001628280-26-028411.md) | [0.0 d](/filings/0001628280-26-050630.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [110](/filings/0001628280-23-035726.md) | [108](/filings/0001628280-24-021113.md) | [110](/filings/0001628280-24-033477.md) | [109](/filings/0001628280-24-044561.md) | [110](/filings/0001628280-25-023196.md) | [112](/filings/0001628280-25-036728.md) | [112](/filings/0001628280-25-047145.md) | [113](/filings/0001628280-26-028411.md) | [112](/filings/0001628280-26-050630.md) | [115](/filings/0001628280-25-047145.md) | [116](/filings/0001628280-26-028411.md) | [115](/filings/0001628280-26-050630.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 114,860,485 at 2026-07-24, from the cover of the [10-Q filed 2026-07-29](/filings/0001628280-26-050630.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.